Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

KPAP Adherence Crossover Study

NCT: NCT06413134 · NOT_YET_RECRUITING

NCT IDNCT06413134
StatusNOT_YET_RECRUITING
Start Date2026-07-01
Completion2026-12-31

Brief Summary

A device able to provide less positive airway pressure (PAP) for the entire duration of inspiration and roughly half the duration of expiration, designated KPAP, is being developed by SleepRes for the treatment of obstructive sleep apnea (OSA). In prior studies, the administration of higher inspiratory than expiratory PAP did not substantially increase treatment efficacy or adherence to continuous PAP (CPAP), which remains low. In our recent investigation, we demonstrated that the addition of a resistor to the CPAP circuit to reduce inspiratory PAP increased subjective comfort. In another study, we showed that KPAP improved subjective comfort during wakefulness vs. fixed CPAP, while maintaining treatment efficacy. The present study, KPAP Adherence 1, is a randomized, crossover study designed to examine whether KPAP can improve adherence over APAP as an at home treatment for OSA.

Frequently Asked Questions

What is KPAP Adherence Crossover Study?

KPAP Adherence Crossover Study is a clinical trial registered under NCT06413134. Current status: NOT_YET_RECRUITING.

What is the status of NCT06413134?

The current status of NCT06413134 (KPAP Adherence Crossover Study) is: NOT_YET_RECRUITING.

When did KPAP Adherence Crossover Study start?

KPAP Adherence Crossover Study started on 2026-07-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.